Journal of Patient Experience (Jun 2023)

Understanding the Challenges Faced by Esophageal and Gastroesophageal Junction Cancer Survivors

  • Erin McGillivray MD,
  • Rishi Jain MD,
  • Chethan Ramamurthy MD,
  • Jennifer Y. Sheng MD,
  • Evgenia Granina MD,
  • Daohai Yu PhD,
  • Xiaoning Lu MS,
  • Abbas E. Abbas MD,
  • Efrat Dotan MD,
  • Joshua E. Meyer MD,
  • Carolyn Y. Fang PhD,
  • Crystal S. Denlinger MD

DOI
https://doi.org/10.1177/23743735231179545
Journal volume & issue
Vol. 10

Abstract

Read online

The primary aim of this study is to characterize long-term quality of life (QOL) in patients with esophageal and gastroesophageal junction (EGEJ) cancers who underwent curative intent treatment. EGEJ survivors were recruited to participate in a one-time cross-sectional survey study using validated questionnaires assessing QOL. Chart review was conducted for patient demographics and clinical characteristics. Spearman correlation coefficients, Wilcoxon signed-rank test, and Fisher's exact test were used to assess relationships between patient characteristics and long-term outcomes. QOL was relatively high in this sample, as evidenced by high median scores on the functional scales and low median scores in the symptom domains of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30, with an overall median global health score of 75.0 (range 66.7-83.3). Patients using opiates at the time of survey reported lower role functioning ( P = .004), social functioning ( P = .052), and overall global health ( P = .041). Younger patients had significantly higher rates of reflux ( P = .019), odynophagia ( P = .045), choking ( P = .005), and cough ( P = .007). Patients using opiates or of younger age had lower QOL and higher symptoms in this cohort of long-term EGEJ survivors.